DOLUTEGRAVIR sodium (DTG), eq. 10mg base, disp. tab.
STD
DORADOLU1TD
Valid Article
HS Code:
300490
Last Updated on:
22/10/2024, 12:18:51
6.4.2.4 - Integrase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AJ03
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
DOLUTEGRAVIR (DTG)
Therapeutic Action
Antiretroviral, Integrase Strand Transfer Inhibitor (INSTI)
Indications
HIV infection, in combination with other antiretrovirals
Instructions for use
The 10 mg dispersible tablet for oral solution is intended for children from at least 4 weeks old and from 3 to 20 kg:
- Do not chew or crush the dispersible tablet.
- Fully disperse in 5 ml of drinking water (for 1 to 3 tab) or 10 ml (for 4, 5 to 6 tablets) in the supplied cup.
- Swirl the suspension until full dispersion.
- Give dose to patient. Add again 5 ml of water to the cup to rinse and administer to patient.
- Administer within 30 minutes of mixing.
In children 20 kg and over, preferably use 50 mg tablet unless they cannot swallow tablets.
When dolutegravir is used in association with other antiretrovirals:
- In children from 6 to 24.9 kg, a fixed-dose combination (FDC) ABC 60mg / 3TC 30mg / DTG 5mg, disp. tab. is available.
- In children from 20 to 30 kg, use dolutegravir 50 mg tablet in combination with a fixed-dose combination (FDC) ABC 120mg / 3TC 60mg, disp. breakable tab.
- In adolescents > 30 kg and adults, a fixed-dose combination (FDC) TDF 300mg / 3TC 300mg / DTG 50mg, tab. is available.
Storage
Below 25ºC - Protect from sunlight - Protect from humidity